Table 4.

OR (95% CI) for case-control and case-case comparisons of the relationship between tertiles of LOC and cyclin E+ and cyclin E- ovarian cancer

Cyclin E+ cases
Cyclin E-cases
Controls
Cyclin E+ cases versus controls
Cyclin E-cases versus controls
Cyclin E+ versus Cyclin E-cases
n (%)n (%)n (%)OR* (95% CI)OR* (95% CI)OR (95% CI)
No. LOC
    All subjects
        <26541 (19)98 (32)193 (32)1.01.01.0
        265-39068 (32)118 (39)200 (33)1.8 (1.1-3.0)1.3 (0.9-1.9)1.3 (0.7-2.2)
        >390104 (49)89 (29)219 (36)2.7 (1.6-4.5)1.0 (0.7-1.5)2.4 (1.3-4.3)
    Premenopausal
        <26524 (34)65 (48)125 (51)1.01.01.0
        265-39027 (39)49 (36)83 (34)2.3 (1.1-4.8)1.2 (0.7-2.1)1.8 (0.7-4.2)
        >39019 (27)22 (16)38 (15)5.2 (2.0-13.9)1.4 (0.7-3.0)3.5 (1.1-10.9)
    Postmenopausal
        <26517 (12)33 (20)68 (19)1.01.01.0
        265-39041 (29)69 (41)117 (32)1.4 (0.8-2.7)1.3 (0.8-2.2)1.0 (0.5-2.2)
        >39085 (59)67 (40)181 (49)2.1 (1.1-3.8)0.9 (0.5-1.5)2.0 (1.0-4.1)
  • * Adjusted for age at diagnosis/interview (cubic spline), race (Black/non-Black), BMI (kg/m2; continuous), tubal ligation (yes/no), family history of breast/ovarian cancer in first-degree relative (yes/no), and infertility (yes/no).

  • Adjusted for age at diagnosis/interview (cubic spline), race (Black/non-Black), BMI (kg/m2; continuous), tubal ligation (yes/no), family history of breast/ovarian cancer in first-degree relative (yes/no), and infertility (yes/no) as well as stage (I/II versus III/IV) and grade (LMP, I/II, or III/IV).